Sort   by:  
 Page size 
Polymyxin B (PB) is introduced into the clinic as the last-line therapy against carbapenem-resistant Klebsiella pneumoniae (CRKP). Unfortunately, increased resistance to PB in Klebsiella pneumoniae (K. pneumoniae) has threatened global health. Resistance of K. pneumoniae ...
2022-03-04 | MTBLS4132 | MetaboLights
TMT-based proteomic approach was used to compare the liver protein expression profiles of cancer cachexia mice and healthy control mice.
ORGANISM(S): Mus Musculus 
2021-01-11 | PXD023497 |

Advanced maternal age is a key factor in female infertility, primarily due to declines in ovarian reserve and oocyte quality. However, the metabolic mechanisms underlying reproductive aging are still poorly understood. Here, we show that uridine levels in the plasma and ovaries of aged mice are s...

2026-03-03 | MTBLS13957 | MetaboLights
Quantitative MS analysis for nuclear proteins from Col-0, atprmt3-2, and suppressor m20.
ORGANISM(S): Arabidopsis Thaliana 
2024-09-05 | PXD055607 |
The associated proteins of PDCD2 identified by mass spectrograph
ORGANISM(S): Arabidopsis Thaliana 
2024-09-05 | PXD055608 |
Early diagnosis is crucial to improve outcomes for pancreatic cancer (PC) patients, however the lack of specific and validated biomarkers for the disease remains challenging. In this study, we analyzed the serum proteome of 12 PC patients and 76 healthy controls (HC), using magnetic bead-based weak ...
ORGANISM(S): Homo Sapiens 
2019-04-25 | PXD013626 |
To explore the effects of rG4-PROTACs on the whole proteome, Hela cells were treated with blank (empty transfection control), rG4 mut_A, rG4_A, or rG4_A plus MG132, and a proteomic analysis was included in the subproject
ORGANISM(S): Homo Sapiens 
2024-11-21 | PXD058113 |
BRAF gain-of-function mutations, particularly BRAF(V600E), affect roughly 10% of all colorectal cancer (CRC) patients, and portend poor prognosis with limited therapeutic interventions. BRAF inhibitors such as Encorafenib are ineffective due to MAP kinase pathway reactivation driven by BRAF dimeriza...
ORGANISM(S): Homo Sapiens 
2025-12-21 | PXD072281 |
BRAF gain-of-function mutations, particularly BRAF(V600E), affect roughly 10% of all colorectal cancer (CRC) patients, and portend poor prognosis with limited therapeutic interventions. BRAF inhibitors such as Encorafenib are ineffective due to MAP kinase pathway reactivation driven by BRAF dimeriza...
ORGANISM(S): Homo Sapiens 
2026-04-19 | PXD077365 |
Sort   by:  
 Page size